U.S. markets open in 9 hours 14 minutes

Kodiak Sciences Inc. (KOD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
83.07+1.20 (+1.47%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close81.87
Open81.44
Bid77.00 x 800
Ask84.00 x 800
Day's Range79.88 - 83.65
52 Week Range42.97 - 171.21
Volume126,290
Avg. Volume350,376
Market Cap4.259B
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-3.36
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est121.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report?
    Zacks

    Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report?

    Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Kodiak Sciences to Present at Upcoming Conferences
    PR Newswire

    Kodiak Sciences to Present at Upcoming Conferences

    Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:

  • Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Kodiak Sciences Inc. (NASDAQ: KOD) Investors
    GlobeNewswire

    Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Kodiak Sciences Inc. (NASDAQ: KOD) Investors

    RADNOR, Pa., May 19, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Kodiak Sciences Inc. (“Kodiak”) (NASDAQ: KOD). Kodiak is a clinical stage biopharmaceutical company which engages in researching, developing, and commercializing therapeutics to treat high prevalence retinal diseases. On May 10, 2021, Kodiak issued a press release “report[ing] business highlights and financial results for the first quarter ended March 31, 2021.” The press release included an update regarding the path to licensure for Kodiak’s product KSI301, a proposed anti-vascular endothelial growth factor medicine. Specifically, Kodiak disclosed that “through our continued engagement with the retina community, we have learned that physicians and retina practices would like to see our labeling for KSI-301 include the option for more frequent dosing.” Accordingly, Kodiak announced the launch of the DAYLIGHT study which will evaluate monthly dosing of KSI-301 in patients with wet AMD [age-related macular degeneration].” Kodiak stated that it “expect[s] recruitment in DAYLIGHT will begin in the summer of 2021, and we plan to include data from this fifth pivotal study of KSI-301 in our initial BLA submission.” Following this news, Kodiak’s stock price fell $13.21 per share, or 13%, to close at $88.41 per share on May 10, 2021. If you are a Kodiak investor and would like to learn more about our investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at info@ktmc.com; or please visit the following link to fill out our online form https://www.ktmc.com/kodiak-sciences-inc-investigation?utm_source=PR&utm_medium=link&utm_campaign=kodiak. Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer & Check, LLPJames Maro, Jr., Esq.Adrienne Bell, Esq.280 King of Prussia RoadRadnor, PA 19087(844) 887-9500info@ktmc.com